ATE482696T1 - Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2 - Google Patents

Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2

Info

Publication number
ATE482696T1
ATE482696T1 AT02784313T AT02784313T ATE482696T1 AT E482696 T1 ATE482696 T1 AT E482696T1 AT 02784313 T AT02784313 T AT 02784313T AT 02784313 T AT02784313 T AT 02784313T AT E482696 T1 ATE482696 T1 AT E482696T1
Authority
AT
Austria
Prior art keywords
cucuminoid
cyclooxygenase
expression
compositions
action
Prior art date
Application number
AT02784313T
Other languages
English (en)
Inventor
John Babish
Terrence Howell
Linda Pacioretty
Original Assignee
Metaproteomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaproteomics Llc filed Critical Metaproteomics Llc
Application granted granted Critical
Publication of ATE482696T1 publication Critical patent/ATE482696T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02784313T 2001-10-26 2002-10-25 Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2 ATE482696T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33506201P 2001-10-26 2001-10-26
PCT/US2002/034456 WO2003035007A2 (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
ATE482696T1 true ATE482696T1 (de) 2010-10-15

Family

ID=23310091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784313T ATE482696T1 (de) 2001-10-26 2002-10-25 Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2

Country Status (14)

Country Link
US (1) US20030096027A1 (de)
EP (2) EP2253314A3 (de)
JP (3) JP2005506996A (de)
KR (1) KR20040054738A (de)
AT (1) ATE482696T1 (de)
AU (2) AU2002348096B2 (de)
CA (1) CA2464334C (de)
DE (1) DE60237836D1 (de)
DK (1) DK1446136T3 (de)
ES (1) ES2353868T3 (de)
MX (1) MXPA04003734A (de)
NZ (1) NZ532560A (de)
PT (1) PT1446136E (de)
WO (1) WO2003035007A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149113A1 (en) 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7666449B2 (en) * 2001-06-20 2010-02-23 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
DE60237836D1 (de) * 2001-10-26 2010-11-11 Metaproteomics Llc Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
KR100993113B1 (ko) * 2002-02-14 2010-11-08 기린 홀딩스 가부시키가이샤 지질대사 개선용 조성물 및 식품
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
CA2489947A1 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
NZ539642A (en) * 2002-10-21 2007-01-26 Metaproteomics Llc Compositions containing extracts from hops in combination with a second component for treating inflammatory response
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
CA2526804A1 (en) * 2003-05-22 2005-05-06 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
ITMI20031098A1 (it) * 2003-05-30 2004-11-30 Indena Spa Composti utili nella terapia del morbo di alzheimer e formulazioni che li contengono
EP1694335A4 (de) * 2003-08-26 2008-12-31 Res Dev Foundation Osteoklastogenese-hemmer und ihre verwendungen
JP2005154390A (ja) * 2003-11-28 2005-06-16 Morishita Jintan Kk 肝保護剤
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
AU2011202586B2 (en) * 2004-02-27 2012-03-22 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
WO2006043671A1 (ja) * 2004-10-22 2006-04-27 Kirin Beer Kabushiki Kaisha 転写因子Ｎｒｆ２活性化剤およびその機能が付与された食品
KR20070086079A (ko) * 2004-11-13 2007-08-27 메타프로테오믹스, 엘엘씨 사이클로옥시게나제-2의 억제를 나타내는 조성물
US20080248131A1 (en) * 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
US20070154576A1 (en) * 2005-12-09 2007-07-05 Tripp Matthew L Protein kinase modulation by hops and Acacia products
WO2007134868A2 (en) * 2006-05-24 2007-11-29 Dsm Ip Assets B.V. 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses
WO2007149481A2 (en) * 2006-06-20 2007-12-27 Metaproteomics, Llc Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
WO2008048410A2 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Diagnostic methods and genetic markers for alzheimer disease
WO2008115783A1 (en) * 2007-03-19 2008-09-25 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
CN101686725A (zh) 2007-04-03 2010-03-31 刚迦·拉贾·高卡拉贾 消炎和抗氧化协同作用的膳食补充组合物
AU2008251756B2 (en) * 2007-05-11 2013-06-06 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
JP2011506464A (ja) * 2007-12-10 2011-03-03 メタプロテオミクス， エルエルシー 癌、血管新生及びそれらに関連する炎症経路の置換１，３−シクロペンタジオン多重標的プロテインキナーゼ・モジュレーター
CN102066303A (zh) * 2008-04-02 2011-05-18 麦特普罗泰欧米克斯有限公司 取代1，3-环戊二酮减弱的内皮炎症以及内皮-单核细胞相互作用
EP2274411A4 (de) * 2008-04-11 2016-01-20 Betal Llc Xanthohumol-zusammensetzungen und verfahren zur behandlung von hautkrankheiten oder -störungen
JP6049639B2 (ja) * 2011-12-28 2016-12-21 マルハニチロ株式会社 クロロフィルｃ含有脱顆粒抑制剤
JP6163084B2 (ja) * 2013-11-11 2017-07-12 キリン株式会社 認知症の予防、治療及び／又は認知機能を改善する組成物、及びこれを用いた医薬、食品
JP6242746B2 (ja) * 2014-05-26 2017-12-06 キリン株式会社 記憶学習機能を向上する医薬、食品、組成物
CN107582962A (zh) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 一种用于慢性萎缩性胃炎的配方及其提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149628A (ja) * 1993-11-30 1995-06-13 Suntory Ltd 脂質代謝改善剤
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
JPH0873369A (ja) * 1994-09-01 1996-03-19 Fuairudo:Kk 健康茶
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US6143303A (en) * 1999-08-14 2000-11-07 Janakiram; Chodavarapu Analgesic anti-inflammatory composition and method of preparing from dodonaea sp
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
DE60237836D1 (de) * 2001-10-26 2010-11-11 Metaproteomics Llc Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines

Also Published As

Publication number Publication date
MXPA04003734A (es) 2005-06-20
EP2253314A2 (de) 2010-11-24
AU2008202916A1 (en) 2008-07-24
AU2008202916B2 (en) 2010-06-03
AU2008202916B8 (en) 2010-06-10
JP2011093918A (ja) 2011-05-12
JP2005506996A (ja) 2005-03-10
WO2003035007A2 (en) 2003-05-01
DK1446136T3 (da) 2011-01-10
ES2353868T3 (es) 2011-03-07
EP1446136A2 (de) 2004-08-18
EP1446136A4 (de) 2007-01-10
EP2253314A3 (de) 2012-08-01
AU2002348096B2 (en) 2008-04-03
NZ532560A (en) 2005-02-25
KR20040054738A (ko) 2004-06-25
DE60237836D1 (de) 2010-11-11
CA2464334C (en) 2012-01-10
WO2003035007A3 (en) 2003-09-18
EP1446136B1 (de) 2010-09-29
PT1446136E (pt) 2010-12-29
US20030096027A1 (en) 2003-05-22
CA2464334A1 (en) 2003-05-01
JP2011068680A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
ATE482696T1 (de) Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2
PT1005271E (pt) Composicao biocida sinergica
EA200700382A1 (ru) Фунгицидные композиции
BR0312479A (pt) Composição de tratamento dos cabelos e/ou couro cabeludo, método de tratamento de caspa e uso de óleo de manjericão
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
DK1369039T3 (da) Synergistiske herbicide fremgangsmåder
ATE188341T1 (de) Konservierungsmittel und verfahren zur behandlung von holz
DE602004030535D1 (de) Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
DK1545587T3 (da) Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
EA200600602A1 (ru) Синергические фунгицидные комбинации биологически активных веществ
ATE347401T1 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
DE60316821D1 (de) Aminobenzothiazolverbindungen mit nos-hemmender wirkung
BRPI0307808A2 (pt) composição inibidora da lipase
DE602005009681D1 (de) Haarbehandlungszusammensetzungen mit einem disaccharid; einer disäure und einer ammoniumionen-quelle
AR030487A1 (es) Una composicion herbicida sinergica de un compuesto de dehidrobenzotiofeno y un inhibidor del fotosistema ii y el metodo para el control sinergico de plantas no deseables con dicha composicion
ATE486567T1 (de) Orale zusammensetzung mit einer ersten zusammensetzung (a) und einer zweiten zusammensetzung (b) zur verwendung als gemische zur getrennten oder aufeinanderfolgenden verwendung in der kosmetischen behandlung des menschlichen körpers
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
SV1999000087A (es) Composiciones fungicidas para plantas de arroz-mejoradas y metodo para controlar plagas de las mismas
DE10394347T5 (de) Eine synergistische Zusammensetzung zur Behandlung von Hyperlipidämie
ATE152879T1 (de) Antiparasitäre zusammensetzung zur verwendung bei tieren
DE602004014941D1 (de) Verwendung von colipase-lipase-hemmern bei der herstellung einer pharmazeutischen zusammensetzung zur prävention von adipositas
DK1568356T3 (da) Forebyggelse af tanderosion ved anvendelse af et colostrumprotein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1446136

Country of ref document: EP